Iranian
Biomedical Journal
Volume 30, Issue 2 (Supplementary 2026)
IBJ 2026, 30(2): 2-2 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohamadali M, Ghanei M, Atyabi S M, Bagheri Khoulenjani S, Irani S. Synergistic Effect of Plasma Modified Curcumin and Nano-Doxorubicin in Breast Cancer Cells. IBJ 2026; 30 (2) :2-2
URL: http://ibj.pasteur.ac.ir/article-1-5490-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5490-en.html
Marjan Mohamadali * 
, Mostafa Ghanei , Seyed Mohammad Atyabi , Shadab Bagheri Khoulenjani , Shiva Irani
, Mostafa Ghanei , Seyed Mohammad Atyabi , Shadab Bagheri Khoulenjani , Shiva Irani
Abstract:
Introduction: Doxorubicin (DOX) is a widely used chemotherapeutic agent for breast cancer. However, its clinical utility is often limited due to severe side effects and the development of resistance. Curcumin (CUR), a natural polyphenol, has demonstrated anticancer activities. This study aimed to inhibit breast cancer (BC) cell growth using a combination therapy of cold plasma-modified nano-CUR and nano-DOX in BC cells.
Materials and Methods: To enhance the hydrophilicity of CUR, cold atmospheric plasma (CAP) modification was performed. The cytotoxic effects of carboxymethyl chitosan (CMC) nanoparticles loaded with plasma-modified CUR and DOX were evaluated on MCF-7 BC cells and L929 fibroblast cells using the MTT assay. Apoptosis was assessed through the Annexin V assay, and real-time PCR was employed to analyze the expression levels of the TP53 and BAX genes.
Results and Discussion: CAP significantly increased the solubility of CUR (p < 0.05). The combination therapy of nano-CUR and nano-DOX significantly inhibited cell proliferation (p < 0.05). The effective dose of plasma-treated nano-CUR in combination with nano-DOX was lower than that of free CUR and free DOX (p < 0.05). This combination therapy resulted in a marked increase in the level of apoptosis (up to 61%) and significantly upregulated the expression of the P53 and BAX genes in MCF-7 cells (p < 0.05), indicating an enhanced induction of programmed cell death.
Conclusion: The CMC-based co-delivery system of plasma-treated nano-CUR and nano-DOX demonstrated synergistic anticancer activity at reduced effective doses. This combined nanotherapeutic system could serve as a promising candidate for the treatment of BC.
Materials and Methods: To enhance the hydrophilicity of CUR, cold atmospheric plasma (CAP) modification was performed. The cytotoxic effects of carboxymethyl chitosan (CMC) nanoparticles loaded with plasma-modified CUR and DOX were evaluated on MCF-7 BC cells and L929 fibroblast cells using the MTT assay. Apoptosis was assessed through the Annexin V assay, and real-time PCR was employed to analyze the expression levels of the TP53 and BAX genes.
Results and Discussion: CAP significantly increased the solubility of CUR (p < 0.05). The combination therapy of nano-CUR and nano-DOX significantly inhibited cell proliferation (p < 0.05). The effective dose of plasma-treated nano-CUR in combination with nano-DOX was lower than that of free CUR and free DOX (p < 0.05). This combination therapy resulted in a marked increase in the level of apoptosis (up to 61%) and significantly upregulated the expression of the P53 and BAX genes in MCF-7 cells (p < 0.05), indicating an enhanced induction of programmed cell death.
Conclusion: The CMC-based co-delivery system of plasma-treated nano-CUR and nano-DOX demonstrated synergistic anticancer activity at reduced effective doses. This combined nanotherapeutic system could serve as a promising candidate for the treatment of BC.
 |
Type of Study: Congress |
Subject:
Related Fields
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |